Exenatide/insulin long acting - Hanmi Pharmaceutical

Drug Profile

Exenatide/insulin long acting - Hanmi Pharmaceutical

Alternative Names: LAPSInsulin Combo; LAPSInsulin115/LAPSCA-Exendine4; HM 14220; Insulin/exenatide long-acting - Hanmi Pharmaceutical; Long-acting insulin 115/exendin-4 combination - Hanmi Pharmaceutical

Latest Information Update: 08 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 05 Nov 2015 GLP-1-RA/insulin drug combination licensed to Sanofi worldwide for the treatment of Type-2 diabetes mellitus
  • 01 Jun 2014 Preclinical trials in Type-2 diabetes mellitus in South Korea (Parenteral) before June 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top